MDWD - MediWound Ltd.
IEX Last Trade
17.87
0.070 0.392%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:29:30 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$17.80
0.07
0.39%
Fundamental analysis
14%
Profitability
0%
Dept financing
26%
Liquidity
75%
Performance
10%
Performance
5 Days
8.49%
1 Month
3.23%
3 Months
5.30%
6 Months
22.53%
1 Year
74.03%
2 Year
55.57%
Key data
Stock price
$17.87
DAY RANGE
N/A - N/A
52 WEEK RANGE
$10.42 - $24.00
52 WEEK CHANGE
$73.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/19/2024
Company detail
CEO: Ofer Gonen
Region: US
Website: mediwound.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: mediwound.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
MediWound Ltd. markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
Recent news